adalimumab-aacf (Idacio) vs infliximab-abda (Renflexis)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TNF-alpha · full Psoriasis pipeline

adalimumab-aacf (Idacio)

Marketed by Fresenius SE & Co. KGaA

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT02660580 · Phase 3 · completed

This was a randomized, double-blind, active-controlled phase 3 trial with 443 participants, using the clinical psoriasis endpoint PASI 75 at Week 16. MSB11022 met the prespecified equivalence criterion versus EU-Humira: the 95% confidence interval for the treatment difference was -7.82% to 4.07%, within the predefined -18% to 18% range.

No aligned efficacy figure on record for this race.

infliximab-abda (Renflexis)

Marketed by Samsung Bioepis and partners

Approved in Psoriasismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-aacf (Idacio)infliximab-abda (Renflexis)
PASI 75—Not reported—Not reported
PASI 90—Not reported—Not reported
PASI 100—Not reported—Not reported
sPGA 0/1—Not reported—Not reported
DLQI, change—Not reported—Not reported

PASI 75

adalimumab-aacf (Idacio)
—Not reported
infliximab-abda (Renflexis)
—Not reported

PASI 90

adalimumab-aacf (Idacio)
—Not reported
infliximab-abda (Renflexis)
—Not reported

PASI 100

adalimumab-aacf (Idacio)
—Not reported
infliximab-abda (Renflexis)
—Not reported

sPGA 0/1

adalimumab-aacf (Idacio)
—Not reported
infliximab-abda (Renflexis)
—Not reported

DLQI, change

adalimumab-aacf (Idacio)
—Not reported
infliximab-abda (Renflexis)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-aacf (Idacio): registry results are on file for Psoriasis, but their comparison mappings are not yet available.

infliximab-abda (Renflexis): no structured comparison results are available for Psoriasis.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-aacf (Idacio)'s landscape · infliximab-abda (Renflexis)'s landscape